Biodesix
Biodesix Q2 Revenues Shoot up but Fall Short of Wall Street Expectations
COVID-19 testing revenues grew to $6.0 million while lung diagnostic revenues rose to $4.8 million and biopharma revenues increased to $1.0 million.
Biodesix Q1 Revenues Soar on COVID-19 Testing
For the three months ended March 31, the firm reported revenues of $28.9 million, compared to $5.1 million in the same period a year ago.
The firm will commercialize its Primary Immune Response assay as a laboratory-developed test to help guide immunotherapy decisions in lung cancer patients.
Biodesix Secures $30M Term Loan
The firm used the proceeds to repay outstanding borrowings of $25.9 million under its existing loan with Innovatus Life Sciences Lending Fund.
Biodesix Q4 Revenues More Than Triple on COVID-19 Testing
For the three months ended Dec. 31, the Boulder, Colorado-based firm reported revenues of $27.0 million compared to $8.3 million in 2019.
Feb 26, 2021
Dec 11, 2020
Biodesix Q3 Revenues Rise Sharply
Nov 23, 2020
Three Investment Banks Initiate Coverage of Biodesix
Oct 28, 2020
Biodesix Prices $72M IPO
Mar 20, 2020
Biodesix, Bio-Rad Partner on Coronavirus Test
Jul 18, 2019
Dec 27, 2018
Nov 7, 2018
Jul 10, 2018